All In Biotech

Drug Trial Radar · NCT06895512

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

A Randomized, Double-blind, Parallel-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 386 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

386

Planned (sponsor's estimate)

Start

Apr 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, parallel-controlled, multicenter, phase III study to compare the efficacy and safety of HLX15-IV in combination with Rd (HLX15-IV-Rd) versus DARZALEX® in combination with Rd (D-Rd) in patients with NDMM who are ineligible for autologous stem cell transplantation (ASCT).

Conditions

  • Newly Diagnosed Multiple Myeloma

Interventions

  • HLX15-IVDrug

    recombinant anti-CD38 human monoclonal antibody injection

  • DarzalexDrug

    recombinant anti-CD38 human monoclonal antibody injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IRC-assessed Week 24 rate of very good partial response (VGPR) or betterTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan hospital, Shanghai

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.